Australia's Pharmaceutical Benefits Scheme Puts Damper On Roche's Avastin Sales
This article was originally published in PharmAsia News
Executive Summary
PERTH, Australia - Sales of the top 20 cancer drugs in Australia totaled $545 million in 2008, representing a growth rate of 30 percent since 2005, according to a recent Datamonitor report